YUNGJIN PHARM. Corporate Governance Report: Efforts to improve governance through bylaw amendments and independent director reinforcement, but absence of dividends and shareholder return policy remains disappointing
[Disclosure Overview] YUNGJIN PHARM. published its corporate governance report for the period Jan 1 to Dec 31, 2025. Major shareholder is KT&G (52.45%). Market cap approx. 252.4B KRW, stock price 1,380 KRW.
[Financial Status] 2025 consolidated revenue 254.3B KRW, operating profit 3.4B KRW, net loss 0.23B KRW. Very weak profitability. No dividends for three consecutive years due to lack of distributable earnings. Priority is to resolve accumulated deficit.
[Governance Strengths] Board comprised of 60% independent directors (3 out of 5), audit committee entirely composed of independent directors ensuring independence. ESG ratings: KCGS integrated B+ (5 consecutive years), Sustinvest AA.
[Governance Weaknesses] Non-compliance with recommending 4-week advance notice for AGM, no CEO succession plan, no mid-to-long-term shareholder return policy, insufficient dividend predictability, all-male board.
[Key Bylaw Amendments] At 64th AGM, changed title 'outside director' to 'independent director', strengthened voting restrictions on audit committee member appointments, expanded proxy voting proof methods.
[Convertible Bond Risk] Outstanding: 1st CB 6.4B KRW (conversion price 2,305 won), 2nd CB 25.1B KRW (conversion price 1,999 won). Current price 1,380 won is below conversion prices, so dilution risk is low currently but could emerge if stock rises.
[AI Comprehensive Analysis]The governance report generally meets legal requirements and shows some improvement efforts, but the absence of core shareholder return policies (dividends, share buybacks) and persistent weak profitability limit shareholder value enhancement. While the lack of subsidiaries and KT&G support provide stability, without earnings improvement, stock price recovery may be limited.